These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study. Chan WM; Lai TY; Liu DT; Lam DS Ophthalmology; 2007 Dec; 114(12):2190-6. PubMed ID: 17599414 [TBL] [Abstract][Full Text] [Related]
8. Intravitreal ranibizumab for pigment epithelium detachment with subfoveal occult choroidal neovascularization: a prospective 24-month case series. Parodi MB; Iacono P; Papayannis A; Kontadakis SD; Cascavilla M; Pierro L; Gagliardi M; Bandello F Am J Ophthalmol; 2013 Jan; 155(1):103-108.e2. PubMed ID: 23022164 [TBL] [Abstract][Full Text] [Related]
9. Intravitreal bevacizumab for treatment of subfoveal idiopathic choroidal neovascularization: results of a 1-year prospective trial. Zhang H; Liu ZL; Sun P; Gu F Am J Ophthalmol; 2012 Feb; 153(2):300-306.e1. PubMed ID: 21982109 [TBL] [Abstract][Full Text] [Related]
10. Effects of ranibizumab in patients with subfoveal choroidal neovascularization attributable to age-related macular degeneration. Rothenbuehler SP; Waeber D; Brinkmann CK; Wolf S; Wolf-Schnurrbusch UE Am J Ophthalmol; 2009 May; 147(5):831-7. PubMed ID: 19217019 [TBL] [Abstract][Full Text] [Related]
11. Single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration. Ahmadieh H; Taei R; Soheilian M; Riazi-Esfahani M; Karkhaneh R; Lashay A; Azarmina M; Dehghan MH; Moradian S BMC Ophthalmol; 2007 Jun; 7():10. PubMed ID: 17555600 [TBL] [Abstract][Full Text] [Related]
12. Intravitreal bevacizumab for myopic choroidal neovascularization: short-term and 1-year results. Spielberg L; Leys A Bull Soc Belge Ophtalmol; 2009; (312):17-27. PubMed ID: 19927486 [TBL] [Abstract][Full Text] [Related]
13. Intravitreal bevacizumab for nonsubfoveal choroidal neovascularization associated with angioid streaks. Battaglia Parodi M; Iacono P; La Spina C; Berchicci L; Scotti F; Leys A; Introini U; Bandello F Am J Ophthalmol; 2014 Feb; 157(2):374-377.e2. PubMed ID: 24211865 [TBL] [Abstract][Full Text] [Related]
14. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration. Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A Retina; 2007; 27(4):432-8. PubMed ID: 17420694 [TBL] [Abstract][Full Text] [Related]
16. Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results. Gharbiya M; Allievi F; Mazzeo L; Gabrieli CB Am J Ophthalmol; 2009 Jan; 147(1):84-93.e1. PubMed ID: 18774547 [TBL] [Abstract][Full Text] [Related]
17. Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up. Wu L; Arevalo JF; Roca JA; Maia M; Berrocal MH; Rodriguez FJ; Evans T; Costa RA; Cardillo J; Retina; 2008 Feb; 28(2):212-9. PubMed ID: 18301025 [TBL] [Abstract][Full Text] [Related]
18. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration]. Bidot ML; Malvitte L; Bidot S; Bron A; Creuzot-Garcher C J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687 [TBL] [Abstract][Full Text] [Related]
19. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Bashshur ZF; Bazarbachi A; Schakal A; Haddad ZA; El Haibi CP; Noureddin BN Am J Ophthalmol; 2006 Jul; 142(1):1-9. PubMed ID: 16815245 [TBL] [Abstract][Full Text] [Related]
20. Intravitreal bevacizumab for choroidal neovascularisation associated with pseudoxanthoma elasticum. Finger RP; Charbel Issa P; Ladewig M; Holz FG; Scholl HP Br J Ophthalmol; 2008 Apr; 92(4):483-7. PubMed ID: 18369065 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]